Hernádi Z, Pásti G, Lampé L, Juhász B
Zentralbl Gynakol. 1985;107(17):1065-71.
Authors report on their experiences concerning in vitro clonogenic assay performed according to Hamburger and Salmon on solid tumor tissue samples (13 cases) and ascites cells (5 cases) obtained from 16 ovarian cancer patient. Out of the 13 solid tumors they got single cell suspension with sufficient number of cells in each case. Colony formation was observed in 10 out of 18 specimens. Dose-response curves were determined after incubation of cells with different concentrations of the following drugs: cis-platin, adriamycin and melphalan. Patients were treated with the CAP combination chemotherapy. The correlation between clinical responses and in vitro sensitivity was evaluated retrospectively. The analysis of the in vitro-in vivo correlation showed that in case of in vitro resistance against two components of the CAP combination the tumor progressed during CAP treatment. In case of in vitro resistance against one component except cis-platin CAP therapy could cause even complete response. By in vitro cis-platin resistance the maximum response with CAP treatment was partial remission.
作者报告了他们根据汉堡和萨尔蒙方法，对16例卵巢癌患者的实体瘤组织样本（13例）和腹水细胞（5例）进行体外克隆形成试验的经验。在13个实体瘤中，他们在每种情况下都获得了细胞数量充足的单细胞悬液。在18个样本中有10个观察到集落形成。在用不同浓度的以下药物（顺铂、阿霉素和马法兰）孵育细胞后，测定剂量反应曲线。患者接受CAP联合化疗。回顾性评估临床反应与体外敏感性之间的相关性。体外-体内相关性分析表明，在对CAP联合化疗的两种成分产生体外耐药的情况下，肿瘤在CAP治疗期间进展。在对除顺铂以外的一种成分产生体外耐药的情况下，CAP治疗甚至可能导致完全缓解。对于体外顺铂耐药，CAP治疗的最大反应为部分缓解。
